By Manas Mishra.
(Reuters) – Johnson & Johnson agreed on Wednesday to buy Momenta Pharmaceuticals Inc. for about $6.5 billion to add muscle to its portfolio of drugs for hard-to-treat autoimmune diseases.
The deal gives J&J’s Janssen unit access to Momenta’s experimental therapy nipocalimab, which is being tested for myasthenia gravis, a neuromuscular disorder that causes muscle weakness, as well as other diseases in which the immune system attacks the body.
J&J hopes the drug will be approved to treat a variety of diseases and eventually lead to blockbuster sales as the company seeks to grow its biggest business with a new class of drugs.
“Janssen will have the potential to launch multiple new drugs, many of which are first-in-class indications, with the potential to achieve significant peak annual sales, some of which could exceed $1 billion,” Johnson & Johnson said in a statement.
Shares of Cambridge, Massachusetts-based Momenta rose 68.8 percent to $52, just shy of its $52.50 offering price.
BTIG analyst Thomas Shrader said: “We find this deal moderately surprising because we think each of Momenta’s assets is a bit tricky to develop.” He added that it was hard to imagine Momenta making a higher bid.
J&J’s offer for Momenta comes days after France’s Sanofi (NASDAQ:) reached a $3.7 billion deal to acquire Principia Biopharma’s (NASDAQ:) pipeline of autoimmune disease treatments.
J&J has sold off divisions in recent years, such as one that makes medical devices for diabetes care, as it focuses more on better-performing businesses such as cancer treatment.
The company, which is also one of the drugmakers bidding to develop a coronavirus vaccine, recently signed agreements with the U.S. and U.K. for potential future vaccine doses.
DISCLAIMER: United Media would like to remind you that the data contained in this website may not be real-time or accurate. All CFD (stock, index, futures) and foreign exchange prices are not provided by exchanges, but by market makers, and therefore prices may not be accurate or may differ from actual market prices, which means that prices are indicative only and are not suitable for trading. Accordingly, Fusion cannot be held liable for any trading losses you may incur as a result of using this data.
Neither Fusion Media nor anyone associated with Fusion Media will be liable for any loss or damage caused by reliance on the information contained within this website, including data, quotes, charts and buy/sell signals. Please fully understand the risks and costs associated with trading in the financial markets, which is the highest risk form of investment.